Acclaimed Dentistry Leader Dr. Ed Zuckerberg Joins Proteocyte in Advisory Role

Toronto, ON; November 15, 2022 – Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient’s risk of developing oral cancer, is pleased to welcome Dr. Ed Zuckerberg as a Senior Advisor.

Joining the company to advance the commercialization process of its oral dysplasia predictive test Straticyte in the U.S. market, Dr. Zuckerberg has an extensive background and ongoing presence in the field of Dentistry. A graduate of NYU College of Dentistry, Dr. Zuckerberg owned his own practices in Brooklyn and Dobbs Ferry, NY from 1979 – 2013 before relocating to California.

Dr. Zuckerberg’s early adoption of technologies including digital radiography, CAD/CAM and others, caught the attention of Industry leaders who enlisted him to lecture, write articles and beta test new technologies. This interest in adopting advanced technologies also helped launch his son Mark’s (the founder of Facebook) interest in computers.

In 2021, Dr. Zuckerberg was named Chief Dental Officer for Keystone Bio, an early clinical stage biopharmaceutical company dedicated to eradicating the known driver of inflammation and disease, Porphyromonas Gingivalis. He also joined Revere Partners, the first independent venture fund for oral health as a venture partner in early 2021.

He lectures nationally and internationally on technology in the Dental Office, consults privately with Dental Practices and advises Dental/Medical technology startups in addition to treating patients part time in Cupertino, CA.

“Dr. Zuckerberg’s addition to the Proteocyte team comes at a great time in our company’s evolution,” says Proteocyte CEO Mark Hammar. “We recently booked our first revenues with Straticyte in both Canada and the United States, and Dr. Zuckerberg’s excellent reputation and professional network will only serve to rapidly accelerate interest among oral health specialists”.

Dr. Zuckerberg’s comments: “Impacted early in life by a close friend who passed away from cancer, I’ve been passionate about educating colleagues and patients about oral cancer and things we can do to prevent it and detect it early. I’m excited to be working with the team at Proteocyte with their ground-breaking technology to enable more accurate treatment where indicated, as well as avoiding unnecessary treatment.”

About Proteocyte

Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.